| INTRODUCTION
Cardiomyopathy (CMP) is a rare disorder with an estimated annual incidence of 1.13-1.24 per 100 000 children. 1, 2 There are several CMP phenotypic subtypes including hypertrophic (HCM), dilated (DCM), restrictive (RCM), left-ventricular non-compaction (LVNC) and arrhythmogenic right ventricular (ARVC) CMP. Primary CMP is considered a genetic disorder with approximately 100 genes implicated in clinical and research studies with majority being sarcomeric or cytoskeletal genes. 3, 4 These gene defects exhibit variable expressivity and variable penetrance. 5, 6 Through currently available clinical genetic testing, disease-causing variants are detected in 30%-60% of HCM or ARVC, and in less than 20% of DCM, LVNC or RCM, 7-9 with a higher yield in those with a positive family history of CMP. 10 Approximately 1000 unique variants associated with HCM have been identified.
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Identifying disease-causing variants in probands allows for screening of asymptomatic family members to assess their risk of developing CMP. 12 However, the recommendations for clinical genetic testing are variable. The Heart Rhythm Society and the European Heart Rhythm Association recommend clinical genetic testing for all patients with a clinical diagnosis of HCM, and for DCM patients with significant cardiac conduction disease. 13 The European
Society of Cardiology recommends genetic testing for patients with HCM who fulfill diagnostic criteria to enable cascade screening of their relatives. 14 In contrast, the American College of Cardiology Foundation and the American Heart Association recommend genetic testing only for patients with an atypical presentation of HCM or when another genetic condition is expected to be the cause. 15 These guidelines are primarily based on adult studies. Furthermore, these guidelines do not recommend type of genetic testing to employ.
Commercially available genetic testing panels are typically offered as either targeted or expanded panels. Targeted CMP gene panels include genes associated with distinct CMP phenotypic subtypes (5-24 genes). Expanded (panCMP) panels screen for a larger number of genes associated with all CMP subtypes (46-72 genes).
Recent reports indicate that although the use of expanded CMP panels may increase diagnostic yield in adults with DCM, this is not true in HCM. 16, 17 Also, most of the variants identified with expanded panel testing in DCM were primarily in the titin gene (TTN), which is typically associated with adult-onset CMP rather than pediatric CMP. 18, 19 Given the differences in the genetic landscape of pediatric and adult-onset CMP, we specifically compared the diagnostic yield of expanded vs targeted panels in pediatric CMP patients. Center for Biotechnology (NCBI) database, ClinVar. 33 The most recent variant classification was used in final analysis.
| METHODS

| Study population
| Variant classification
| Statistical methods
For the purpose of analysis, "likely pathogenic" and "presumed pathogenic" variants were coded as pathogenic; "likely benign" variants were coded as "benign" (and excluded from analysis); variants for which there was uncertainty regarding pathogenicity were classified as VUS. 3 | RESULTS
| Patient characteristics
The study cohort consisted of 151 eligible phenotype-positive index cases including 66 HCM, 64 DCM, 8 RCM and 13 LVNC. Patient characteristics are described in Table 2 . There were more males in the HCM than in the DCM and RCM/LVNC groups. A higher proportion of HCM patients had a positive family history of CMP compared to DCM or RCM/LVNC.
| Panel test types
In the overall cohort, 104 patients (69%) were tested with a targeted panel and 47 (31%) with a panCMP panel. 117 patients were tested with a single panel and 34 with multiple panels as shown in Figure 1B shows the distribution of panels by CMP subtypes and diagnostic yield for each category.
| Detection of pathogenic variants and VUS in overall cohort
A total of 188 variants were initially reported as pathogenic (n = 49) or VUS (n = 139). Overall, 16% of all variants (n = 31), which were found in 26 patients, were reclassified by accessing the most recent classification by a clinical laboratory on ClinVar (Table 3) . Twentyseven percent of pathogenic variants (n = 13) were reclassified to VUS or benign variants, and 13% of VUS (n = 18) were reclassified to pathogenic or benign variants (see Table 3 for details). Reclassification data was not available for variants initially reported as benign. 
| Variant distribution in CMP genes
The 40 pathogenic variants were identified in 8 genes: MYH7
(n = 16), MYBPC3 (n = 12), TNNI3 (n = 4), TNNT2 (n = 3), VCL (n = 2), LMNA (n = 1), ACTC1 (n = 1), and TTR (n = 1). All these 8 genes harboring pathogenic variants overlapped both targeted and panCMP panels ( Figure 3 ). The most frequently implicated genes in HCM patients were MYH7 and MYBPC3 with 96% (24/25) of the detected pathogenic variants being found in MYH7 or MYBPC3. There was no dominant gene in the other CMPs.
The 133 VUS were identified in 33 genes. The gene that most frequently harbored VUS was TTN (n = 46) (9% HCM, 28% DCM, 50% RCM, 0% LVNC), followed by MYH7 (n = 13) and MYBPC3
(n = 13). VUS were detected in 14 genes common to target and panCMP panels and in 19 genes unique to the panCMP panel. Therefore, unlike pathogenic variants that were only found in genes that overlapped targeted and panCMP panels, 59% of VUS were in genes unique to the panCMP panel ( Figure 3 ).
| DISCUSSION
CMP is a genetically heterogeneous disorder with a large number of genes involved in disease causation. The growing gene list, compounded by the overlap in genes that cause different CMP subtypes, has led to the development of expanded gene panels that include all CMP-associated genes rather than smaller panels targeted to specific CMP subtypes. However, recent reports are conflicting regarding the yield with expanded gene panels in mixed cohorts of adult and pediatric patients. 16, 35 We analyzed the diagnostic yield of expanded vs targeted gene panels specifically in 151 pediatric CMP patients.
An important finding of our study was that despite the larger number of genes tested on a panCMP panel, the diagnostic yield was not higher with panCMP panel testing compared to targeted panel testing in any type of CMP. In addition, when panCMP panel was used as a primary panel, it did not identify any pathogenic variants that would not otherwise have been detected through targeted testing as they were all in genes that overlapped targeted panels. This result is consistent with a previous study by Alfares et al, in which 368 HCM probands (pediatric and adult) were tested on a panCMP panel and no pathogenic variants were detected that were not represented in targeted HCM panels. 16 In contrast to HCM, 2 studies in DCM patients reported an increase in positive test yield with expanded panel testing-from 10%
to 37% in the study by Pugh et al, 35 and to 48% in the study by Haas et al, which is much higher than the yield on expanded panel testing in our cohort. 21 However, the latter study used considerably less stringent criteria for pathogenicity because they used Human Genome Mutation Database (HGMD) annotation rather than the clinical criteria employed in our study. Population-based exome research suggests that a high number of variants with ascribed pathogenicity in the HGMD database are probably modest disease modifiers or non-pathogenic. 36 Therefore, although expanded panels may potentially improve diagnostic utility in adult DCM, we did not observe an increased yield on panCMP panel testing in our pediatric DCM population.
The lower yield in our cohort was probably also related to the lack of involvement of TTN, the gene most commonly associated with adult-onset DCM. At the time of the study, TTN was only included in expanded panels, not in targeted panels. MYH7 and MYBPC3 were the top genes harboring pathogenic variants in HCM patients in our cohort (96%), which is similar to the finding by Alfares et al. 16 However, unlike adult DCM where variants in PKP2 21 or TTN are major contributors to DCM, accounting for 14% of pathogenic variants in DCM patients, 35 we did not find any pathogenic variants in TTN or PKP2 in our young cohort. This suggests that the genetic landscape of pediatric CMP may differ from adult-onset CMP, which may further explain why the panCMP panels may have less utility in pediatric DCM.
Broadening the search to a larger gene panel runs the risk of generating findings of uncertain significance as seen by the almost 3-fold higher yield of VUS with panCMP panels in our study. Pugh et al similarly reported that expanded panel testing increased the detection of pathogenic variants but also increased the percentage of inconclusive cases from 4% to 51%. 35 This is probably due to limitations in our knowledge of variants in some of the less commonly involved genes which makes accurate variant interpretation challenging. The role of the less commonly involved genes (or genes of uncertain significance) may be especially unclear in certain phenotypic subtypes. 36 It also explains why 59% of VUS were reported in less commonly involved genes that were unique to the panCMP panel. It further emphasizes the importance of regularly revisiting variant interpretation as interpretation can change over time as more data become available through testing labs or in the public domain. Interlab variability in variant-calling practices can also contribute to variant reclassification with time. In this regard, 13% of VUS were reclassified to either pathogenic or benign during follow-up either by the original testing lab or by another testing lab in our study, but so were 27% of pathogenic variants over the same time period probably due to increased stringency in the recent era for calling a variant pathogenic.
This highlights that the vast majority of variants remained of unknown significance despite reclassification over a median followup of 3.9 years.
While it may be tempting to continue to offer expanded panels for clinical testing in the hopes of improving our ability to accurately classify new variants or reclassify VUS over time as more knowledge about genotype-phenotype relationships accrued, it is worth noting that only 4 of 139 initially reported VUS were reclassified to pathogenic while 12 of the 49 initially reported pathogenic variants were reclassified to VUS during the course of our study. If VUS are less frequently reclassified to pathogenic than vice versa, collecting greater numbers of VUS may be unhelpful for diagnosis. We also must consider that reclassifying variants can cause emotional distress for patients and their families, especially when rescreening is suggested.
An improvement in our accuracy of variant interpretation can only be accomplished through access to larger libraries of comprehensive sequencing data in carefully phenotyped CMP patients and well-documented controls, availability of affected and unaffected family members for segregation analyses, and ability to rapidly A, PanCMP panel testing had a lower detection rate of pathogenic variants compared to targeted panels (15% vs 32%, P = .03) and a higher detection rate of VUS (87% vs 30%, P < .0001); B, The yield of pathogenic variants and VUS was not significantly different between the CMP subtypes regardless of panel type. However, VUS variant yield remained higher with panCMP vs targeted panels across all CMP subtypes, that is, 89% vs 23% for HCM (P = .0002), 88% vs 41% for DCM (P = .0002), and 83% vs 33% for RCM/LVNC (P = .06) respectively. C, The yield on primary panCMP testing was higher than secondary panCMP testing for both pathogenic variants (21% vs 0%, P = .09) and VUS (94% vs 71%, P = .06). CMP, cardiomyopathy; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; RCM, restrictive cardiomyopathy; LVNC, left-ventricular non-compaction; VUS, variant of unknown significance, panCMP, expanded cardiomyopathy panel FIGURE 3 Graph showing genes harboring pathogenic variants (black bars) and VUS (grey bars). Genes on left side represent genes that overlap both targeted and panCMP panels and genes on right side represent genes unique to panCMP panel. All the pathogenic variants were only detected in genes overlapping both panel types. 59% of the VUS were detected in genes unique to the panCMP panel. Even if diagnostic yield of expanded panels improves, it is worth noting that these panels currently only cover a subset of all the potential CMP-causing genes. An unbiased approach using clinical exome or whole-genome sequencing has the potential to reveal more causal variants compared to expanded panels as reported by Waldmuller et al. 40 In fact, it is rapidly becoming more cost-effective to perform clinical exome sequencing when searching within a large gene set rather than continuing to expand the gene panels. 41, 42 Taking this a step further, whole-genome sequencing has been applied by Golbus et al to identify rare pathogenic variants in patients with DCM. 43 They identified pathogenic and probably pathogenic variants in 9 of 11 subjects with DCM using whole-genome sequencing, an 82% detection rate that surpasses targeted and expanded panel detection rates. However, clinical utility of whole-exome or wholegenome sequencing is also critically dependent on the ability to accurately classify pathogenicity of variants. Therefore, although clinical exome or genome sequencing is currently not routinely offered in CMPs, it may become an important tool for gene-elusive and complex
CMPs as accuracy of variant classification improves.
Our study limitations include a relatively small sample size that precluded subgroup analyses for some CMP subtypes. Also, the evolution of sequencing technology probably contributed to variation in diagnostic yield over time due to better sequence capture and sequencing depths, and also because of enhanced confidence in pathogenicity prediction of variants with growing experience in testing labs. We tried to reduce this bias by reclassifying variants based on the most recent clinical interpretations available on ClinVar for each variant. We did not reevaluate variants on ClinVar that were originally interpreted as benign or probably benign by the testing laboratory, which could have resulted in an underestimation of the number of clinically significant variants.
In conclusion, our results suggest that expanded panel testing 
